VKH
ANIX icon

Virtu KCG Holdings’s Anixa Biosciences ANIX Stock Holding History

Virtu KCG Holdings’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$14K Buy
+12,549
New +$17.4K ﹤0.01% 2751

Other funds holding ANIX

BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DIA
Denver Investment Advisors Denver, Colorado $1.89B AUM 7.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Virtu KCG Holdings's ANIX Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Anixa Biosciences (ANIX) in Q2 2017: 12,549 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #2751 among its holdings.

14 funds tracked by Wall St. Rank hold ANIX as of Q2 2017.

  • Virtu KCG Holdings held 12,549 shares of Anixa Biosciences worth $14K as of Q2 2017.
  • Anixa Biosciences was a new Virtu KCG Holdings position in Q2 2017.
  • Anixa Biosciences made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2751 holding.
  • 14 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.